FDA launches a neuroscience program spanning its drug, biologics and device centers
The Neuroscience Advancement and Innovation Nexus will work on science, tools and regulatory approaches for brain and nervous system products, starting with Alzheimer's prevention trials.
The FDA announced the Neuroscience Advancement and Innovation Nexus (NAIN) on October 22, a program to advance the science, tools and regulatory approaches behind medical products for brain and nervous system conditions. It draws on the agency’s drug and biologics centers as well as its Center for Devices and Radiological Health.
The first initiative, the Alzheimer’s Prevention Accelerator, will look at trial populations, endpoints and evidence standards for preventing or delaying the disease. The release gives no funding figures and does not mention brain-computer interfaces or neuromodulation directly, so what NAIN means for neurotechnology developers is not yet clear.
Learn more: Clinical trial pathway · FDA CDRH